

Weina Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3561618/publications.pdf>

Version: 2024-02-01

27
papers

1,091
citations

516215

16
h-index

525886

27
g-index

36
all docs

36
docs citations

36
times ranked

1179
citing authors

#	ARTICLE	IF	CITATIONS
1	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. <i>Nature Medicine</i> , 2021, 27, 106-114.	15.2	204
2	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 80-91.	4.6	103
3	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020, 62, 103132.	2.7	77
4	Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. <i>Journal of Virology</i> , 2017, 91, .	1.5	70
5	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020, 8, 771.	2.1	61
6	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	5.8	61
7	Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach. <i>Journal of Virology</i> , 2019, 93, .	1.5	53
8	Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. <i>Journal of Clinical Investigation</i> , 2018, 128, 4992-4996.	3.9	51
9	A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. <i>Npj Vaccines</i> , 2019, 4, 31.	2.9	40
10	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. <i>MBio</i> , 2021, 12, e0190821.	1.8	32
11	An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations. <i>PLoS ONE</i> , 2018, 13, e0194830.	1.1	27
12	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. <i>EClinicalMedicine</i> , 2022, 45, 101323.	3.2	26
13	Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
14	Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. <i>Journal of Virology</i> , 2019, 93, .	1.5	21
15	Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals. <i>Journal of Virology</i> , 2020, 94, .	1.5	19
16	The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. <i>Journal of Virology</i> , 2018, 92, .	1.5	18
17	Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase. <i>Journal of Virology</i> , 2019, 93, .	1.5	18
18	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. <i>Npj Vaccines</i> , 2019, 4, 51.	2.9	18

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. <i>Vaccine</i> , 2022, 40, 3621-3632.	1.7	15
20	Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus. <i>Molecular Pharmaceutics</i> , 2021, 18, 679-698.	2.3	14
21	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. <i>Frontiers in Immunology</i> , 2021, 12, 791764.	2.2	14
22	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	3.7	14
23	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	14
24	An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains. <i>Vaccines</i> , 2019, 7, 117.	2.1	12
25	Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
26	Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 746447.	2.2	9
27	An Egg-Derived Sulfated N-Acetylglucosamine Glycan Is an Antigenic Decoy of Influenza Virus Vaccines. <i>MBio</i> , 2021, 12, e0083821.	1.8	8